Aripiprazole is generally well tolerated with little weight gain but some patients may experience what associated side- effect?

A. Akathisia: Aripiprazole is a partial dopamine D2 agonist, which can lead to overstimulation of dopaminergic pathways in some patients. This mechanism commonly causes akathisia, characterized by inner restlessness and an urge to move, even though the drug has minimal metabolic or prolactin-related side effects. B. Cataracts: Cataracts are not associated with aripiprazole use. This side effect is more relevant to medications such as quetiapine in rare cases or chronic corticosteroid use, and it does not result from dopamine or serotonin modulation. C. Hyperprolactinemia: Aripiprazole has minimal impact on prolactin because its partial agonist activity at D2 receptors maintains some dopaminergic inhibition of prolactin release. Therefore, significant elevations in prolactin are uncommon. D. Diabetic Ketoacidosis: Aripiprazole carries a low metabolic risk and is unlikely to precipitate severe hyperglycemia or diabetic ketoacidosis. While monitoring is still important, DKA is extremely rare with this agent.